Buy Rating Maintained for Apellis Pharmaceuticals: Strategic Market Position and Growth Potential Justify Price Objective

TipRanksJan 11 23:39 · Ratings

Apellis Pharmaceuticals Down Over 14%, on Pace for Largest Percent Decrease Since December 2023 -- Data Talk

Dow JonesJan 11 00:30

Express News | Apellis Pharmaceuticals Inc - Board Expands to Seven Directors, Six Independent

BreakingsJan 10 20:05

Express News | Apellis Announces Keli Walbert to Join the Board of Directors

BreakingsJan 10 20:00

Press Release: Apellis Announces Keli Walbert to Join the Board of Directors

Dow JonesJan 10 20:00

Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)

TipRanksJan 10 19:46 · Ratings